Pat Beyer - Oct 29, 2021 Form 4 Insider Report for CONMED Corp (CNMD)

Role
President Int'l & Global Ortho
Signature
/s/ Sarah M. Oliker for Pat Beyer by Power of Attorney
Stock symbol
CNMD
Transactions as of
Oct 29, 2021
Transactions value $
-$8,075,751
Form type
4
Date filed
11/2/2021, 04:59 PM
Previous filing
May 18, 2021
Next filing
Nov 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNMD Common Stock Options Exercise $2.2M +55.3K +708.34% $39.87 63.1K Oct 29, 2021 Direct
transaction CNMD Common Stock Tax liability -$4.34M -30K -47.57% $144.62 33.1K Oct 29, 2021 Direct
transaction CNMD Common Stock Sale -$403K -2.79K -8.43% $144.50 30.3K Oct 29, 2021 Direct F1
transaction CNMD Common Stock Sale -$2.46M -16.9K -55.79% $145.31 13.4K Oct 29, 2021 Direct F2
transaction CNMD Common Stock Sale -$817K -5.59K -41.72% $146.14 7.81K Oct 29, 2021 Direct F3
transaction CNMD Common Stock Options Exercise $2.6M +50.7K +649.42% $51.30 58.5K Oct 29, 2021 Direct
transaction CNMD Common Stock Tax liability -$4.86M -33.3K -56.84% $146.28 25.3K Oct 29, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNMD Options To Purchase Common Stock Options Exercise $0 -55.3K -100% $0.00* 0 Oct 29, 2021 Common Stock 55.3K $39.87 Direct F4
transaction CNMD Sars (Stock Appreciation Rights) Options Exercise $0 -50.7K -100% $0.00* 0 Oct 29, 2021 Common Stock 50.7K $51.30 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.90 to $144.88. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.92 to $145.92. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.93 to $146.53. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F4 The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.
F5 The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Plan and generally vest in equal amounts (20%) over a five year period.